You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Microcapillary Quartz Sensors for Screening Injectability of High Concentration Protein Formulations

    SBC: QATCH TECHNOLOGIES LLC            Topic: None

    The objective of this SBIR Phase I proposal is to determine the feasibility of viscosity characterization of high concentration protein formulations (HCF) by QATCH’s microcapillary quartz technology. HCFs are non-Newtonian fluids with shear-thinning behavior and they are administered to patients by subcutaneous or muscular injections. The injectability of HCFs depends on the viscosity at high-sh ...

    SBIR Phase I 2019 Department of CommerceNational Institute of Standards and Technology
  2. Nanomachine Device for Semiconductor Process Control Monitoring

    SBC: XALLENT INC.            Topic: None

    Conventional characterization and test methods are increasingly ineffective when applied to structures less than 100 nanometers, causing challenges across R&D, process control and failure analysis. An increasing number of subtle defects become prominent drivers of failure as device size and operating margins decrease, e.g., processing anomalies in thin gate oxides, substrate problems related to do ...

    SBIR Phase I 2019 Department of CommerceNational Institute of Standards and Technology
  3. Biphase Extended Release Tablet Formulation for Nerve Agent Pretreatment

    SBC: ZYMERON CORP            Topic: CBD181004

    Nerve agents exert their toxic effect by binding to and inactivating enzyme acetylcholinesterase, a key enzymatic regulator of cholinergic neurotransmission. The binding becomes irreversible after a varying amount of time with nerve agents and this aging process limits the treatment window of oxime reactivators. To enhance the current antidote treatment of nerve agent autoinjectors, a pyridostigmi ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government